Assessing the benefits of lipid-lowering therapy

American Journal of Cardiology

Volumn 82, Issue 6 SUPPL. 1, 1998, Pages

  Gotto Jr , Antonio M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT;

BLOOD; CAUSE OF DEATH; CORONARY ARTERY ATHEROSCLEROSIS; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; HYPERLIPIDEMIA; MORTALITY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL; TREATMENT OUTCOME;

ANTILIPEMIC AGENTS; CAUSE OF DEATH; CORONARY ARTERIOSCLEROSIS; COST-BENEFIT ANALYSIS; HUMANS; HYPERLIPIDEMIAS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0032563784     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00526-8     Document Type: Article

References (27)

1. Anitschkow NN. A history of experimentation on arterial atherosclerosis in animals. In: Blumenthal HT, ed. Cowdry's Atherosclerosis. 2nd ed. Springfield, IL: Charles C Thomas, 1967.
2. Müller C. Xanthomata, hypercholesterolemia, angina pectoris. Acta Med Scand 1938;89(suppl):75-84.
3. Thannhauser SJ, Magendantz H. The different clinical groups of xanthomatous disease: a clinical physiological study of 22 cases. Ann Intern Med 1938;11: 1662-1746.
4. Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of athero-sclerotic disease: new perspectives based on the Framingham Study. Ann Intern Med 1979;90:85-91.
5. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361 662 men. Lancet 1986;ii:933-939.
6. Neaton JD, Blackburn H, Jacobs D, Kuller L, Lee DJ, Sherwin R, Shih J, Stamler J, Wentworth D . Multiple Risk Factor Intervention Trial Research Group. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Arch Intern Med 1992;152:1490-1500.
7. LaRosa JC. Unresolved issues in early trials of cholesterol lowering. Am J Cardiol 1995;76(suppl):5C-9C.
8. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-374.
9. Frick MH. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987;317:1237-1245.
10. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. Br Med J 1990;301:309-314.
11. Committee of Principal Investigators. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978;40:1069-1118.
12. Gibaldi M, Kradjan W. Treating elevated cholesterol levels: the great satan in perspective. J Clin Pharmacol 1996;36:189-197.
13. Hulley SB, Walsh JMB, Newman TB. Health policy on blood cholesterol: time to change directions. Circulation 1992;86:1026-1029.
14. Smith GD, Pekkanen J. Should there be a moratorium on the use of cholesterol-lowering drugs? Br Med J 1992;304:431-434.
15. Marchioli R, Marfisi RM, Carini F, Tognoni G. Meta-analysis, clinical trials, and transferability of research results into practice: the case of cholesterollowering interventions in the secondary prevention of coronary heart disease. Arch Intern Med 1996;156:1158-1172.
16. Kronmal RA. Commentary on the published results of the Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 1985;256:2091-2093.
17. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W, for the Coronary Drug Project Research Group. Fifteen-year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-1255.
18. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988;223:405-418.
19. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
20. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
21. Roussow JE, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction. N Engl J Med 1990;323:1112-1119.
22. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 1998;97:946-952.
23. 1997 Heart and Stroke Statistical Update. Dallas: American Heart Association; 1997.
24. Sempos CT, Cleeman JI, Carroll MD, Johnson CL, Bachorik PS, Gordon DJ, Burt VL, Briefel RR, Brown CD, Lippel K, et al. Prevalence of high blood cholesterol among US adults: an update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel. JAMA 1993;269:3009-3014.
25. Jacobson TA. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor therapy in the managed care era. Am J Cardiol 1996;78:32-41.
26. Goldman L, Garber AM, Grover SA, Hlatky MA. Task force 6: cost-effectiveness of assessment and management of risk factors. J Am Coll Cardiol 1996;27:1020-1030.
27. Curtiss FR. Lessons learned from projects in disease management in ambulatory care. Am J Health Syst Pharm 1997;54:2217-2229.